ClinicalTrialStartPulse: Phase 2, page 3 of 4
Records 201 to 350 of the 500 newest listed for this hub. Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
| Record | Phase | Conditions | Enrollment |
|---|---|---|---|
| Hutchmed | Phase 2 | Solid Tumor, Adult | 147 |
| XYone Therapeutics, Inc | Phase 2 | MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; GEJ Adenocarcinoma; Colorectal Cancer; Pancreatic Adenocarcinoma | 190 |
| Biothervax SpA | Phase 2 | Respiratory Syncytial Virus Infection Prevention; Tuberculosis Prevention | 200 |
| Medicines Development for Global Health | Phase 2 | Erythema Nodosum Leprosum | 45 |
| Children's Hospital Medical Center, Cincinnati | Phase 2 | Allogeneic Stem Cell Transplantation | 256 |
| Johns Hopkins University | Phase 2 | Mood (Psychological Function); Well Being; Mood; Healthy | 20 |
| National Human Genome Research Institute (NHGRI) | Phase 2 | Focal Segmental Glomerulosclerosis; Minimal Change Disease; Membranous Nephropathy | 30 |
| Tanta University | Phase 2 | SBP - Spontaneous Bacterial Peritonitis | 60 |
| Tanta University | Phase 2 | SBP - Spontaneous Bacterial Peritonitis | 60 |
| National Cancer Institute (NCI) | Phase 2 | Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma; Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma; Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma; Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma; Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma; Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma | 87 |
| City of Hope Medical Center | Phase 2 | Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma; Gastric Mucosa-Associated Lymphoid Tissue Lymphoma; Marginal Zone Lymphoma; Nodal Marginal Zone Lymphoma; Splenic Marginal Zone Lymphoma; Lymphoma | 35 |
| University Health Network, Toronto | Phase 2 | Triple-Negative Breast Cancer (TNBC) | 60 |
| Swiss Cancer Institute | Phase 2 | B-cell Lymphoma | 92 |
| Columbia University | Phase 2 | Hypernatremia | 80 |
| Fred Hutchinson Cancer Center | Phase 2 | Locally Advanced Bladder Urothelial Carcinoma; Locally Advanced Renal Pelvis Urothelial Carcinoma; Locally Advanced Ureter Urothelial Carcinoma; Metastatic Bladder Giant Cell Urothelial Carcinoma; Metastatic Renal Pelvis Urothelial Carcinoma; Metastatic Ureter Urothelial Carcinoma | 27 |
| Massachusetts General Hospital | Phase 2 | Lymphoma; B-cell Lymphomas; Relapsed/Refractory Large B-cell Lymphoma; Large B-cell Lymphoma | 56 |
| BioNTech SE | Phase 2 | Advanced Solid Tumors | 173 |
| Akeso | Phase 2 | Prurigo Nodularis (PN) | 132 |
| Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 | Metabolic Dysfunction-associated Steatohepatitis (MASH) | 181 |
| BeOne Medicines | Phase 2 | Waldenstrom Macroglobulinemia; Waldenstrom's Macroglobulinemia Recurrent; Waldenstrom's Macroglobulinemia Refractory | 114 |
| Pfizer | Phase 2 | Hidradenitis Suppurativa | 128 |
| Immuneering Corporation | Phase 2 | Advanced Solid Tumor; Pancreatic Adenocarcinoma; Malignant Melanoma (Cutaneous); Non-small Cell Lung Cancer (NSCLC) | 209 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 2 | Acute Ischemic Stroke | 210 |
| 3D Medicines (Sichuan) Co., Ltd. | Phase 2 | Solid Tumor | 188 |
| Pfizer | Phase 2 | Pneumococcal Disease | 605 |
| Zura Bio Inc | Phase 2 | Hidradenitis Suppurativa (HS) | 247 |
| Arcus Biosciences, Inc. | Phase 2 | Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Cancer; Lung Cancer | 169 |
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Phase 2 | Metabolic Dysfunction-Associated Steatoic Liver Disease | 120 |
| Avalyn Pharma Inc. | Phase 2 | Pulmonary Fibrosis; Progressive Pulmonary Fibrosis; Pulmonary Fibrosis Secondary to Systemic Sclerosis; Pulmonary Fibrosis, Interstitial Lung Disease; Interstitial Lung Disease; Interstitial Lung Disease Due to Connective Tissue Disease (Disorder) | 398 |
| Merck Sharp & Dohme LLC | Phase 2 | Advanced Solid Tumors; Malignant Neoplasm | 300 |
| Akeso | Phase 2 | Chronic Spontaneous Urticaria | 201 |
| Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 2 | Non Small Cell Lung Cancer | 220 |
| Ausper Biopharma Co., Ltd. | Phase 2 | Chronic Hepatitis B | 105 |
| Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Phase 2 | Systemic Lupus Erythematosus | 381 |
| Incyte Corporation | Phase 2 | Chronic Graft-versus-host-disease | 130 |
| Hoffmann-La Roche | Phase 2 | Multiple Sclerosis | 193 |
| Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | Phase 2 | Inflammatory Bowel Diseases; Colitis, Ulcerative | 280 |
| RemeGen Co., Ltd. | Phase 2 | Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology | 200 |
| Stemline Therapeutics, Inc. | Phase 2 | Hematological Malignancy | 115 |
| Astellas Pharma Global Development, Inc. | Phase 2 | Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma | 393 |
| Kyowa Kirin Co., Ltd. | Phase 2 | Diabetic Macular Edema (DME) | 185 |
| Vincentage Pharma Co., Ltd | Phase 2 | Type 2 Diabetes Mellitus (DM) | 120 |
| SMSbiotech | Phase 2 | Chronic Obstructive Lung Disease | 125 |
| Eisai Co., Ltd. | Phase 2 | Solid Neoplasms | 125 |
| Ascendis Pharma Oncology Division A/S | Phase 2 | Advanced Solid Tumor; Locally Advanced Solid Tumor; Metastatic Solid Tumor; Platinum-resistant Ovarian Cancer; Post Anti-PD-1 Melanoma; 2L+ Cervical Cancer | 320 |
| AstraZeneca | Phase 2 | Hepatocellular Carcinoma | 114 |
| Pfizer | Phase 2 | Overweight; Obesity; Overweight and/or Obesity; Overweight or Obesity; Overnutrition; Nutrition Disorders | 940 |
| Merck Sharp & Dohme LLC | Phase 2 | Pulmonary Sarcoidosis | 158 |
| Genuine Seed Therapeutics (Zhuhai) Co., Ltd. | Phase 2 | RAS-mutant Advanced Solid Tumors | 172 |
| Servier Bio-Innovation LLC | Phase 2 | Non-small Cell Lung Cancer (NSCLC) | 102 |
| Rhythm Pharmaceuticals, Inc. | Phase 2 | Hypothalamic Obesity; Prader-Willi Syndrome; PWS | 111 |
| Nob Hill Therapeutics, Inc. | Phase 2 | NSCLC (Advanced Non-small Cell Lung Cancer) | 100 |
| AOBiome LLC | Phase 2 | Acne Vulgaris | 176 |
| Merck Sharp & Dohme LLC | Phase 2 | Pain Management | 380 |
| Agomab Spain S.L.U. | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | 120 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 2 | Non-small Cell Lung Cancer | 660 |
| RayzeBio, Inc. | Phase 2 | Prostate Cancer (Adenocarcinoma); Adenocarcinoma of the Prostate; Metastatic Castration-resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC); Biochemical Recurrence (BCR); High-Risk Localized Prostate Cancer | 116 |
| KymaThera, Inc. | Phase 2 | Breast Neoplasms; Solid Tumors; PIK3CA Gene Mutation | 110 |
| Amgen | Phase 2 | Small Cell Lung Cancer (SCLC) | 252 |
| Genmab | Phase 2 | Relapsed/Refractory Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Richter's Syndrome; Treatment-naïve High Risk Chronic Lymphocytic Leukemia | 194 |
| Genmab | Phase 2 | DLBCL; High-grade B-cell Lymphoma (HGBCL); Primary Mediastinal Large B-cell Lymphoma (PMBCL); FL; MCL; Small Lymphocytic Lymphoma (SLL) | 666 |
| Immunwork, Inc. | Phase 2 | Overweight and Obesity | 204 |
| CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 2 | Advanced/Metastatic Solid Tumors | 140 |
| Serum Institute of India Pvt. Ltd. | Phase 2 | Diptheria Immunization; Tetanus Immunization; Pertussis Immunization; Hepatitis B Immunization; Haemophilus InfluenzaeType B Immunization; Polio Immunization | 186 |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 | Non-Squamous Non-Small Cell Lung Cancer | 110 |
| TransThera Sciences (Nanjing), Inc. | Phase 2 | Mantle Cell Lymphoma (MCL) | 188 |
| Blueprint Medicines Corporation | Phase 2 | Indolent Systemic Mastocytosis | 251 |
| Hoffmann-La Roche | Phase 2 | Non-Hodgkins Lymphoma | 211 |
| Zhejiang Doer Biologics Co., Ltd. | Phase 2 | Hypertriglyceridemia | 315 |
| Ranok Therapuetics Co. Ltd. | Phase 2 | Advanced Gynecologic Malignancies | 120 |
| Aclaris Therapeutics, Inc. | Phase 2 | Atopic Dermatitis; Atopic; Dermatitis; AD; Eczema | 110 |
| Transcenta Therapeutics (Hangzhou) Co., Ltd. | Phase 2 | Locally Advanced Solid Tumor; Metastatic Tumor; Colorectal Adenocarcinoma | 111 |
| AstraZeneca | Phase 2 | Non-small Cell Lung Cancer | 194 |
| Eli Lilly and Company | Phase 2 | Obesity; Overweight | 367 |
| Shanghai Ruotuo Biosciences Co., Ltd. | Phase 2 | Advanced Malignant Solid Tumours | 308 |
| Guangzhou JOYO Pharma Co., Ltd | Phase 2 | Atopic Dermatitis (AD) | 160 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 2 | Type 2 Diabetes | 240 |
| GlaxoSmithKline | Phase 2 | Meningitis, Meningococcal | 305 |
| Genentech, Inc. | Phase 2 | Chronic Lymphocytic Leukemia | 118 |
| GlaxoSmithKline | Phase 2 | Respiratory Syncytial Virus Infections | 168 |
| Darwin Origin (Hubei) Biopharmaceutical Co., Ltd. | Phase 2 | Ischemic Stroke in the Sequelae Stage | 200 |
| Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 | Acute Gouty Arthritis | 132 |
| Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 2 | Non-Cystic Fibrosis Bronchiectasis | 234 |
| PharmaMar | Phase 2 | Advanced Solid Tumor | 231 |
| Wockhardt | Phase 2 | Complicated Urinary Tract Infections(cUTI); Acute Pyelonephritis | 279 |
| Verve Therapeutics, Inc. | Phase 2 | Atherosclerosis; Cardiovascular Disease; Hypercholesterolemia | 175 |
| Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 | Sjögren's Disease | 198 |
| Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 2 | Hypertension | 560 |
| CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 2 | Advanced Solid Tumors | 400 |
| Redx Pharma Ltd | Phase 2 | Strictures Due to Crohn's Disease | 180 |
| Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Phase 2 | Hypertension; Resistant Hypertension; Uncontrolled Hypertension | 240 |
| Attovia Therapeutics Inc | Phase 2 | Chronic Pruritus of Unknown Origin | 300 |
| Darwin Origin (Hubei) Biopharmaceutical Co., Ltd. | Phase 2 | Amyotrophic Lateral Sclerosis (ALS) | 150 |
| Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 | Obesity; Heart Failure With Preserved Ejection Fraction (HFPEF); Heart Failure With Mildly Reduced Ejection Fraction | 141 |
| Sanofi | Phase 2 | Asthma | 556 |
| Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 | Hypertension | 352 |
| AstraZeneca | Phase 2 | Ovarian Cancer; Breast Cancer; Pancreatic Cancer; Prostate Cancer; Additional Indications Below for Module 4 and 5; Non-small Cell Lung Cancer | 702 |
| Eli Lilly and Company | Phase 2 | Urinary Bladder Neoplasms; Urologic Neoplasms; Receptor, Fibroblast Growth Factor, Type 3 | 161 |
| AbelZeta Inc. | Phase 2 | Multiple Sclerosis; Primary Progressive Multiple Sclerosis; Secondary Progress Multiple Sclerosis (SPMS); Primary Progressive Multiple Sclerosis (PPMS); MS; MS (Multiple Sclerosis) | 119 |
| Zhejiang Anglikang Pharmaceutical Co., Ltd. | Phase 2 | Advanced Gastrointestinal Tumors | 174 |
| Novo Nordisk A/S | Phase 2 | Obesity | 233 |
| Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 | Diffuse Large B-Cell Lymphoma | 204 |
| SIGA Technologies | Phase 2 | Smallpox | 100 |
| Hoffmann-La Roche | Phase 2 | Alzheimers Disease | 241 |
| Pfizer | Phase 2 | Breast Cancer; Solid Tumors | 235 |
| National Cancer Institute (NCI) | Phase 2 | Chronic Graft vs Host Disease; Chronic Graft-Versus-Host Disease; Bronchiolitis Obliterans Syndrome | 16 |
| National Cancer Institute (NCI) | Phase 2 | Respiratory Tract Diseases; Neoplasms; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Neoplasms, Squamous Cell; Tumor Virus Infections | 21 |
| National Cancer Institute (NCI) | Phase 2 | Metastatic Prostate Cancer; Prostatic Neoplasms; Prostate Cancer; Prostatic Cancer; Prostate Neoplasms | 98 |
| Washington University School of Medicine | Phase 2 | Triple Negative Breast Cancer; Triple Negative Breast Cancer (TNBC); Breast Cancer | 17 |
| The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | 32 |
| Olivia Newton-John Cancer Research Institute | Phase 2 | Peripheral T-Cell Lymphoma Refractory | 25 |
| Fudan University | Phase 2 | Gastric Adenocarcinoma; Gastroesophageal Junction (GEJ) Adenocarcinoma | 62 |
| National Cancer Center, Japan | Phase 2 | Ovarian Clear Cell Carcinoma | 32 |
| University of Calgary | Phase 2 | Cancer; Colorectal Cancer | 90 |
| Medical University of South Carolina | Phase 2 | Bipolar Disorder; Alcohol Use Disorder | 70 |
| Mayo Clinic | Phase 2 | Covid19 | 80 |
| M.D. Anderson Cancer Center | Phase 2 | SMARCB1-Deficient Malignancies; Epithelioid Sarcoma; Renal Medullary Carcinoma | 15 |
| M.D. Anderson Cancer Center | Phase 2 | Gland; Salivary Gland Cancers | 63 |
| M.D. Anderson Cancer Center | Phase 2 | Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8 | 4 |
| M.D. Anderson Cancer Center | Phase 2 | Lymphoma | 16 |
| National Cancer Institute (NCI) | Phase 2 | Adult Ovarian Granulosa Cell Tumor | 17 |
| University of Minnesota | Phase 2 | ARDS, Human; Lung, Wet; Thyroid; Pulmonary Edema; Lung Inflammation | 19 |
| University of Washington | Phase 2 | Mantle Cell Lymphoma | 27 |
| Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Small Cell Lung Cancer (SCLC); SCLC, Extensive Stage | 25 |
| National Health Research Institutes, Taiwan | Phase 2 | Biliary Tract Cancer (BTC) | 55 |
| Aarhus University Hospital | Phase 2 | Breast Cancer (Early Breast Cancer); Obesity | 32 |
| M.D. Anderson Cancer Center | Phase 2 | Lung Cancer | 13 |
| Memorial Sloan Kettering Cancer Center | Phase 2 | Mycosis Fungoides; Mycosis Fungoides/Sezary Syndrome; Sezary Syndrome; Sézary; Advanced Mycosis Fungoides | 14 |
| M.D. Anderson Cancer Center | Phase 2 | Mantle Cell Lymphoma | 50 |
| M.D. Anderson Cancer Center | Phase 2 | Metastatic Malignant Female Reproductive System Neoplasm | 28 |
| Yunnan Cancer Hospital | Phase 2 | Breast Neoplasms; Advanced Breast Cancer; HER2-positive Breast Cancer; HER2-low Breast Cancer | 56 |
| Tanta University | Phase 2 | Irreversible Pulpitis | 40 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Prostate Cancer (Adenocarcinoma) | 37 |
| Anhui Provincial Hospital | Phase 2 | Penile Squamous Cell Carcinoma (PSCC); Advanced Penile Cancer; Metastatic Penile Cancer; Locally Advanced Penile Cancer | 31 |
| Ain Shams University | Phase 2 | Pulmonary Hypertension | 60 |
| University of Washington | Phase 2 | Diffuse Large B-Cell Lymphoma; Grade 3b Follicular Lymphoma; High Grade B-Cell Lymphoma | 33 |
| Memorial Sloan Kettering Cancer Center | Phase 2 | Diffuse Large B-cell Lymphoma (DLBCL); Relapsed Diffuse Large B-cell Lymphoma (DLBCL); Refractory Diffuse Large B-cell Lymphoma (DLBCL) | 59 |
| New York State Psychiatric Institute | Phase 2 | Obsessive-Compulsive Disorder | 18 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 | Dystonia; Focal Dystonia; Musician's Dystonia | 5 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Idiopathic CD4 T Cell Lymphocytopenia | 54 |
| National Cancer Institute (NCI) | Phase 2 | Thymoma; Thymic Carcinoma | 56 |
| National Cancer Institute (NCI) | Phase 2 | Lymphoproliferative Disorder; HHV-8; Malignancy; HIV | 75 |
| Fujian Cancer Hospital | Phase 2 | Gastric/Gastroesophageal Junction Adenocarcinoma; Oligometastatic Peritoneal Metastasis | 42 |
| Anhui Provincial Cancer Hospital | Phase 2 | Gastric Cancer (Diagnosis) | 32 |
| Centre Hospitalier St Anne | Phase 2 | Primary Angiitis of the Central Nervous System (PACNS) in Remission | 74 |
| University of Sulaimani | Phase 2 | Plaque-Induced Gingivitis | 60 |
| Azienda Ospedaliero-Universitaria Careggi | Phase 2 | Breast Cancer (Advanced/Metastatic) | 60 |
| University Health Network, Toronto | Phase 2 | T2D | 20 |
| Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Multiple Myeloma (MM) | 55 |
| West China Hospital | Phase 2 | Colo-rectal Cancer | 32 |
All ClinicalTrialStartPulse record reports